Holen Sie sich die Stockscreener-App
15.90
0.00%
0.00
Handel nachbörslich:
15.81
-0.09
-0.57%
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
RLYB stock hits 2-year highs after unveiling merger with Avenzo – how much of the new company will Rallybio shareholders own? - MSN
Rallybio Company Profile & Introduction - Moomoo
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
JOHNSON & JOHNSON's Rallybio Corp(RLYB) Holding History - GuruFocus
San Diego Biotech Upstart Avenzo Plots Nasdaq Splash In Rallybio Reverse Merger - Hoodline
United StatesMintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics’ And Rallybio’s Merger Transaction - Mondaq
Avenzo Picks Up Reverse Merger Ditched by Candid - San Diego Business Journal
ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB) - Stock Titan
RLYB Stock Chart | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock - Investing.com
Mintz Advising on $215 Million Private Placement Concurrent with Avenzo Therapeutics’ and Rallybio’s Merger Transaction - Mintz
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - Business Wire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corpo - GuruFocus
Halper Sadeh LLC is Investigating Whether RLYB, KALV, INM, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders - PR Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing - The Pharma Letter
Rallybio to Raise $215M Via Pvt Placement >RLYB - Moomoo
Rallybio: Placement Expected to Fund Ops Into Late 2028 >RLYB - Moomoo
Rallybio: Combined Co Expected to Operate As Avenzo Therapeutics >RLYB - Moomoo
RLYB: Merger leverages oncology expertise and $215M funding to advance clinical programs and milestones - TradingView
RLYB: Merger accelerates oncology pipeline with $215M funding and late 2028 cash runway - TradingView
Rallybio finds a new reverse-merger dance partner in Avenzo - FirstWord Pharma
RallyBio tries again for reverse merger, this time with Avenzo - BioPharma Dive
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders - marketscreener.com
RLYB: Rallybio to Merge with Avenzo Therapeutics in Strategic Ac - GuruFocus
EDGAR Filing Documents for 0001193125-26-249801 - SEC.gov
Rallybio and Avenzo Therapeutics Announce Merger and $215 Million Private Placement to Advance Next-Generation Oncology Therapies – Minichart - Minichart
Rallybio to merge with Avenzo Therapeutics in $215M deal - grafa.com
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing - Endpoints News
After failed deal, Rallybio announces new merger; New Haven HQ to close - Hartford Business Journal
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio - Pharmaceutical Executive
Rallybio to Merge With Avenzo Therapeutics in Oncology-Focused Reverse Merger Backed by $215 Million Financing - citybiz
Rallybio swerves past Candid pothole to land deal with Avenzo - Fierce Biotech
Rallybio to acquire Avenzo in $215 million merger deal By Investing.com - Investing.com South Africa
Rallybio to acquire Avenzo in $215 million merger deal - Investing.com
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement - Business Wire
Rallybio amends employment and separation agreements for Stephen Uden, Jonathan Lieber and Steven Ryder - TradingView
Rallybio (RLYB) to combine with Avenzo; $215M concurrent financing backing deal - Stock Titan
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):